Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Acevedo-Gadea

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Histopathology|December 10, 2015
Expression of CD30 as a biomarker to predict response to brentuximab vedotinMina L Xu, Carlos Acevedo-Gadea, Stuart Seropian, et al.
American Journal of Hematology|August 30, 2008
ADAMTS13 activity and inhibitorAdriana Doldan-Silvero, Carlos Acevedo-Gadea, Clandine Habib, et al.
Breast Cancer Research and Treatment|February 18, 2015
Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapyCarlos Acevedo-Gadea, Christos Hatzis, Gina Chung, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 22, 2014
Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancerCarlos Acevedo-Gadea, Alessandro D Santin, Susan A Higgins, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Histopathology|December 10, 2015
Expression of CD30 as a biomarker to predict response to brentuximab vedotinMina L Xu, Carlos Acevedo-Gadea, Stuart Seropian, et al.
American Journal of Hematology|August 30, 2008
ADAMTS13 activity and inhibitorAdriana Doldan-Silvero, Carlos Acevedo-Gadea, Clandine Habib, et al.
Breast Cancer Research and Treatment|February 18, 2015
Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapyCarlos Acevedo-Gadea, Christos Hatzis, Gina Chung, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 22, 2014
Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancerCarlos Acevedo-Gadea, Alessandro D Santin, Susan A Higgins, et al.
Pageof 1